Edition:
India

ADMA Biologics Submits Response And Provides Supplemental Information To FDA For Bivigam Complete Response Letter


Monday, 7 Jan 2019 

Jan 7 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS SUBMITS RESPONSE AND PROVIDES SUPPLEMENTAL INFORMATION TO FDA FOR BIVIGAM® COMPLETE RESPONSE LETTER.ADMA BIOLOGICS INC - ANTICIPATES RECEIVING AN ACKNOWLEDGEMENT LETTER FROM FDA WITHIN 30 DAYS. 

Company Quote

4.62
-0.06 -1.28%
18 Apr 2019